AUSTIN, TX and DURHAM, NC, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will participate in a fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium, taking place February 12-13, 2026.

Conference Details

Conference: Piper Sandler Virtual Novel Targets in Immunology Symposium

Format: Fireside chat

Presenters: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer, Andrew R. Neill, Chief Financial Officer, and Michael Choi, M.D., Vice President of Clinical Development

Presentation Date: February 12, 2026

Time: 2:00 PM ET

Webcast link: HERE

A replay of the prerecorded presentation from the Piper Sandler Virtual Novel Targets in Immunology Symposium fireside chat will be available on the Events and Presentations section of the Company's website starting at 2:00 PM ET on Thursday, February 12, 2026. A replay of the webcast will be archived for up to 30 days following the presentation date.

About SL-325

SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck's preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. SL-325 is a fully Fc-silenced humanized immunoglobin G monoclonal antibody with a favorable safety profile in non-human primates, currently being evaluated in a Phase 1 clinical trial.

About Shattuck Labs, Inc.

Shattuck Labs, Inc. (NASDAQ:STTK) is a clinical-stage biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. Shattuck's expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor & Media Contact:

Andrew R. Neill

Chief Financial Officer

Shattuck Labs, Inc.

InvestorRelations@shattucklabs.com

Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium